
==== Front
BiologicsBiologicsBiologics: Targets and TherapyBiologics : Targets & Therapy1177-54751177-5491Dove Medical Press 10.2147/BTT.S54093btt-7-231CorrigendumTreatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum] 2013 2013 31 10 2013 7 231 231 © 2013 Keohane et al. This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License2013The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed.
==== Body
Keohane C, Radia DH, Harrison CN. Biologics: Targets and Therapy. 2013;7:189–198.

On page 193 note that the paragraph beginning “Pacritinib (SB1518; Cell Technology, Inc, Mountain View, CA, USA) is a JAK2 and FLT3 inhibitor currently being evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts (<50 × 109/L).” should have been “Pacritinib (SB1518; Cell Therapeutics, Inc, Seattle, WA, USA) is a JAK2 and FLT3 inhibitor which was evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts (<50 × 109/L).”

On page 193 in the same paragraph note that “Post-Essential Thrombocythemia Myelofibrosis: PERSIST).” should have been “Post-Essential Thrombocythemia Myelofibrosis-1: PERSIST-1).”
